NCX 470 New Drug Application (NDA) filing in the United States: expected in H1 2026. NCX 470 New Drug Application (NDA) filing in China: expected after submission in the U.S. Results from NCX 470 ...
(RTTNews) - Nicox SA announced the signing of a new agreement concerning NCX 470 with Kowa, a Japanese company. The agreement, worth up to 191.5 million euros, grants Kowa exclusive rights to develop ...
Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that once daily dosing of NCX 470 0.1%, a novel nitric oxide (NO)-donating bimatoprost ...
(RTTNews) - Nicox SA announced the results of the Whistler Phase 3b exploratory clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback